USA: A target trial emulation study revealed that denosumab significantly increased the risk of hypocalcemia requiring ...

Hypocalcemia is a condition that occurs when ... Having very low levels of calcium can cause you to develop severe fatigue. "We suggest that fatigue may be caused by hypocalcaemia more frequently ...

For patients with chronic kidney disease (CKD), the risk for emergently treated hypocalcemia with denosumab increases with ...

The Food and Drug Administration (FDA) has added a new boxed warning on the denosumab drug label (brand name: Prolia) to alert clinicians to an increased risk for severe hypocalcemia in patients with ...

Low levels of calcium – an important nutrient that keeps your bones strong and healthy- can lead to a condition known as ...

The researchers found that with denosumab vs oral bisphosphonates, the risk for emergently treated hypocalcemia increased with worsening CKD stage. (HealthDay News) — For patients with chronic ...

Throughout 2024, the FDA issued new drug approvals and expanded treatment indications across various rheumatologic diseases.

Denosumab treatment for osteoporosis appears more hazardous in postmenopausal women with advanced chronic kidney disease (CKD).